
The panelists discussed why treatment sequencing in chronic lymphocytic leukemia (CLL) no longer follows a single algorithm now that Bruton tyrosine kinase (BTK) inhibitors and venetoclax are available alone or together in the frontline setting.

The panelists discussed why treatment sequencing in chronic lymphocytic leukemia (CLL) no longer follows a single algorithm now that Bruton tyrosine kinase (BTK) inhibitors and venetoclax are available alone or together in the frontline setting.

The panelists discussed chimeric antigen receptor (CAR) T-cell therapy for patients with chronic lymphocytic leukemia (CLL) who have failed both covalent Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

The panelists discussed the role of venetoclax-based therapy in relapsed chronic lymphocytic leukemia (CLL), including venetoclax-rituximab as a time-limited standard supported by long-term survival data, while noting that few patients in its pivotal trial had received a prior Bruton tyrosine kinase (BTK) inhibitor.

The panelists discussed how safety profiles influence Bruton tyrosine kinase (BTK) inhibitor selection for patients with chronic lymphocytic leukemia (CLL) and cardiovascular disease, emphasizing the absence of head-to-head comparisons among acalabrutinib, zanubrutinib, and pirtobrutinib.

The panelists discussed triplet regimens combining a Bruton tyrosine kinase (BTK) inhibitor, venetoclax, and obinutuzumab for chronic lymphocytic leukemia (CLL), noting higher rates of undetectable measurable residual disease than with doublets.

The panelists discussed how they individualize frontline treatment for chronic lymphocytic leukemia (CLL) now that fixed-duration and continuous regimens both hold strong guideline support.

The panelists discussed how to differentiate Bruton tyrosine kinase (BTK) inhibitors when selecting treatment for chronic lymphocytic leukemia (CLL), beginning with mechanism.